四价人乳头瘤病毒疫苗（酿酒酵母）(Human papillomavirus quadrivalent (types 6, 11, 16, 18) vaccine, recombinant(Emmanuel College, University of Queensland))

概要

基本信息

药物类型

预防性疫苗、重组亚单位疫苗

别名

Human papillomavirus (types 6, 11, 16, 18) L1 VLP vaccine、Human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine、Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine

+ [12]

靶点-

作用机制-

治疗领域

肿瘤感染消化系统疾病+ [2]

在研适应症

肛门癌前病变乳头状瘤病毒感染原位腺癌+ [7]

非在研适应症

急性缺血性卒中系统性红斑狼疮阴道腺癌+ [3]

原研机构

Emmanuel College, University of Queensland

在研机构

Merck Sharp & Dohme BV

Merck Sharp & Dohme Corp.

Merck & Co., Inc.

非在研机构

Merck Sharp & Dohme Ireland Ltd.Merck Sharp & Dohme LLC

SK bioscience Co., Ltd.

最高研发阶段批准上市

首次获批日期

美国 (2006-06-08),

乳头状瘤病毒感染

最高研发阶段(中国)批准上市

特殊审评-

登录后查看首次获批时间轴

关联

108

项与四价人乳头瘤病毒疫苗（酿酒酵母）相关的临床试验

NCT06142461 / Not yet recruiting临床2期

Safety and Immunogenicity of Human Papillomavirus Quadrivalent Vaccine Administered Intradermally and Intramuscularly Via Needle-Free Injection System

The goal of this clinical trial is to evaluate the safety and immunogenicity of an HPV Vaccine (Gardasil) delivered by intramuscular needle-free injection and intradermal needle-free injection. The main question it aims to answer is:
Is intramuscular and intradermal needle-free injection of Gardasil safe?
Does intramuscular and intradermal needle-free vaccination with Gardasil illicit an immune response?
Participants will:
Receive Gardasil by intramuscular needle-free injection, intradermal needle-free injection, or needle and syringe injection.
Provide blood samples
Complete physical exams
Complete diaries

开始日期2024-05-31

申办/合作机构

PharmaJet, Inc.

[+2]

IRCT20240120060741N1 / Suspended临床3期

Clinical trial of the immunogenicity and safety of Papilloguard 4 vaccine (quadrivalent manufactured by Nivad Pharmed Salamat company) compared to Gardasil vaccine (quadrivalent, reference product, Merck company) by comparing the ratio of GMT (Geometric Mean Titer) in healthy male and female volunteers 15 to 25 years: a phase 3 randomized, parallel, double-blind, noninferiority clinical trial

开始日期2024-04-20

申办/合作机构-

CTIS2022-502224-49-00 / Recruiting

Human papillomavirus vaccine effectiveness study among men who have sex with men

开始日期2023-01-27

申办/合作机构-

100 项与四价人乳头瘤病毒疫苗（酿酒酵母）相关的临床结果

登录后查看更多信息

100 项与四价人乳头瘤病毒疫苗（酿酒酵母）相关的转化医学

登录后查看更多信息

100 项与四价人乳头瘤病毒疫苗（酿酒酵母）相关的专利（医药）

登录后查看更多信息

679

项与四价人乳头瘤病毒疫苗（酿酒酵母）相关的文献（医药）

2024-12-31·Human vaccines & immunotherapeutics

High impact of quadrivalent human papillomavirus vaccine across racial/ethnic groups: National Health and Nutrition Examination Survey, 2003-2006 and 2015-2018.

Article

作者: Ruth Stefanos ; Rayleen M Lewis ; Troy D Querec ; Julia W Gargano ; Elizabeth R Unger ; Lauri E Markowitz

Human papillomavirus (HPV) causes cervical as well as other cancers. Racial and ethnic disparities in cervical cancer incidence and mortality in the United States are well documented. HPV vaccination has been recommended in the United States since 2006 and is expected to prevent HPV-attributable cancers in all racial/ethnic groups. Quadrivalent HPV vaccine-type (HPV6/11/16/18) and nonvaccine-type cervicovaginal HPV prevalences were estimated from National Health and Nutrition Examination Surveys in 2015-2018 (vaccine era) and 2003-2006 (prevaccine era) data. Prevalence ratios comparing 2015-2018 to 2003-2006 were calculated among sexually experienced Non-Hispanic White (NHW), Non-Hispanic Black (NHB), and Mexican American (MA) females aged 14-24 years. Quadrivalent HPV vaccine-type prevalence declined 82% (CI: 60%-92%) among NHW, 86% (CI: 64%-95%) among NHB, and 100% among MA females, forecasting future reductions in cervical cancer across racial/ethnic groups.

2024-03-01·Vaccine: X

National launch of human papillomavirus (HPV) immunization program in Poland, 2023.

Article

作者: Irmina Maria Michalek ; Paweł Koczkodaj ; Joanna Didkowska

Poland launched a nationwide Human Papillomavirus (HPV) immunization program in June 2023, transitioning from a recommended to publicly funded approach. Targeting mainly 12 to 13-year-olds, the program offers universal and cost-free vaccinations with Cervarix and Gardasil 9. The initiative, aligned with the National Oncology Strategy, involves 4945 healthcare facilities, ensuring accessibility across regions. The streamlined process, empowering parents to choose, includes diverse healthcare professionals.

2024-02-24·The Laryngoscope

Adjuvant Human Papillomavirus Vaccination in Recurrent Respiratory Papilloma Patients Older than 45.

Article

作者: Ryan Ivancic ; Taylor Freeman ; Brad de Silva ; Arick Forrest ; Brandon Kim ; Laura Matrka

OBJECTIVES:

The primary objective was to examine the intersurgical interval (ISI) of recurrent respiratory papillomatosis (RRP) in patients older than 45 years before and after a Gardasil vaccination series.

METHODS:

We conducted a retrospective chart review of adult patients >45 years of age diagnosed with RRP from 2012 to 2022. Patients were excluded if they did not receive at least two doses of the Gardasil vaccine series or if they underwent two or fewer surgeries during the study period.

RESULTS:

Thirteen patients met the inclusion criteria, 11 males and two females. The age at initial diagnosis ranged from 46 to 80 years, with a mean of 59 years. There was a significant increase in the average ISI, from 126 ± 87 days pre-vaccination compared to 494 ± 588 days post-vaccination (p < 0.01). The average number of surgeries per patient was 6.8 ± 2.4 over an average follow-up of 49.7 ± 30.3 months.

CONCLUSION:

Adjuvant Gardasil use in RRP patients older than 45 years significantly increases the ISI. Current CDC recommendations include only patients ages 9 to 45, but this study provides evidence that RRP patients outside this age range may benefit from adjuvant HPV vaccination.

LEVEL OF EVIDENCE:

4 Laryngoscope, 2024.

306

项与四价人乳头瘤病毒疫苗（酿酒酵母）相关的新闻（医药）

2024-04-05

·FiercePharma

AbbVie retains ad spending leadership, but some surprise drugs make the top 10 in March

Total spending for March was $188 million, up from $168.4 million in February. This is still some way off the $200 million-plus we saw tallied up for most months toward the end of 2023. It’s as you were at the top of the pharma drug ad spending list in March as AbbVie’s immunology blockbusters Rinvoq and Skyrizi stay first and second, respectively. This is the same order as we saw in February, according to data from real-time ad trackers at iSpot.TV, with spending also barely moving across both drugs and their spots. However, the third position saw a significant shift. This spot is usually reserved for Sanofi and Regeneron’s rival immunology giant Dupixent, but, in March, Otsuka and Lundbeck's Rexulti took its place. After spending just under $11 million in February and not being listed, Rexulti ads jumped right into the final podium position in March as the pair spent $24.8 million on three spots. Bristol Myers Squibb’s moderate to severe plaque psoriasis drug Sotyktu also jumped into the top 10 after not being in the listing at all the month before, more than doubling spending from $8.6 million in February to $19 million in March. Dupixent has dropped down to fifth place from its usual ranking, while Merck's Gardasil HPV vaccine has made an unexpected appearance at No. 6 on the list of ad spending. Gardasil's ad spending saw a major boost from $7,600 to $14.7 million month over month. In seventh place is Astellas’ hot flash treatment Veozah, down three places, while BMS makes its second entry into the top 10 with its skin, lung and many other cancers immunotherapy Opdivo. Opdivo has over time been in these top 10 lists—but never consistently—and it remains unusual to see any cancer med in these listings, given that it’s not a general drug for common conditions like psoriasis or asthma. BMS was, however, clearly feeling flush as it also splashed out $14 million on ads for a third drug, namely its obstructive hypertrophic cardiomyopathy treatment Camzyos. Rounding off the top 10 is UCB’s moderate to severe plaque psoriasis therapy Bimzelx, which saw exactly $0 spent in February and rose to $13.6 million in March, as it launched its first DTC campaign in time for the Oscars. Total spending for March was $188 million, up from $168.4 million in February. This is still some way off the $200 million-plus we saw tallied up for most months toward the end of 2023, but still a strong showing so early in the year, when overall spending numbers tend to be lower. Check out the top 10 pharmaceutical drug ad spenders as compiled for Fierce Pharma Marketing by iSpot.TV below. 1. Rinvoq Movement: No change What is it? AbbVie’s JAK inhibitor immunology drug Est. national TV ad spend: $31 million (up from $30.1 million in February) Number of spots: Six (one eczema, two arthritis, three UC/Crohn’s) Biggest-ticket ad: “Mountains” (est. $8.6 million) 2. Skyrizi Movement: No change What is it? AbbVie’s immunology drug Est. national TV ad spend: $24.8 million (down from $24.9 million in February) Number of spots: Eight (four psoriasis, one Crohn’s, three psoriatic arthritis) Biggest-ticket ad: “Sailing” (est. $12.5 million) 3. Rexulti Movement: Not listed last month What is it? Otsuka and Lundbeck’s atypical antipsychotic Est. national TV ad spend: $23.4 million (up from $10.8 million in February) Number of spots: Three (two Alzheimer’s, one depression) Biggest-ticket ad: “Still Masking” (est. $18.8 million) 4. Sotyktu Movement: Not listed last month What is it? Bristol Myers Squibb’s moderate to severe plaque psoriasis drug Est. national TV ad spend: $19 million (up from $8.6 million in February) Number of spots: Three Biggest-ticket ad: “Live Unfiltered” (est. $16 million) 5. Dupixent Movement: Down two spots What is it? Sanofi and Regeneron’s immunology drug. Est. national TV ad spend: $18.7 million (down from $20.3 million in February) Number of spots: Seven (three eczema, three asthma, one gastrointestinal) Biggest-ticket ad: “DU More: Diving Board, Soccer and Playground” (est. $7.7 million) 6. Gardasil Movement: Not listed last month What is it? Merck's HPV vaccine Est. national TV ad spend: $14.7 million (up from $7.6K in February) Number of spots: One Biggest-ticket ad: “Numbers Move You” (est. $14.7 million) 7. Veozah Movement: Down three spots What is it? Astellas’ hot flash treatment Est. national TV ad spend: $14.4 million (down from $16.2 million in February) Number of spots: One Biggest-ticket ad: “Not Flash” (est. $14.4 million) 8. Opdivo Movement: Up one spot What is it? Bristol Myers Squibb’s cancer medicine Est. national TV ad spend: $14.4 million (up from $11.3 million in February) Number of spots: One Biggest-ticket ad: “Advanced Lung Cancer” (est. $14.4 million) 9. Camzyos Movement: Down four spots What is it? Bristol Myers Squibb’s symptomatic obstructive hypertrophic cardiomyopathy treatment Est. national TV ad spend: $14 million (down from $16 million in February) Number of spots: Two Biggest-ticket ad: “Mike” (est. $7.9 million) 10. Bimzelx Movement: Not listed last month What is it? UCB’s moderate to severe plaque psoriasis therapy Est. national TV ad spend: $13.6 million (up from $0 in February) Number of spots: Three Biggest-ticket ad: “Born With Wings” (est. $12 million)

疫苗财报免疫疗法临床结果抗体药物偶联物

2024-03-29

·CPHI制药在线

二价HPV疫苗，价格跌破100元

关注并星标CPHI制药在线没有最低，只有更低。根据江苏政府采购网发布的二价HPV疫苗采购成交公告，万泰生物凭借86元/支的价格，成功中标499206支2价HPV疫苗的采购项目。显然，面对竞争加剧以及2价疫苗卖不动的现状，万泰生物决定发动价格战进行反击。那么，跌破100元的2价HPV疫苗，能卖得动吗？/ 01 /2价疫苗价格战拥有首个获批上市的国产二价HPV疫苗馨可宁，万泰生物曾有过一段“躺赚”的日子。当时，GSK的二价HPV疫苗全程接种费用为1740元。万泰生物作为后来者，果断发起价格战。2020年5月，馨可宁获批上市，最初其定价为每针329元，9岁至14岁女性接种两针，全程费用为658元；超过14岁的女性接种三针，全程费用为987元。凭借国产价格优势，万泰生物抢占了极大的市场份额。根据公开信息，2020年馨可宁的批签发量达246万支，2021年批签发量预计达1000万支，占当年国内四款HPV疫苗批签发总量约2700万支中的约37%。到了2022年，馨可宁的销量更是显著增长，年销量突破2500万支。由此，万泰生物疫苗板块的收入显著增长，从2020年8.65亿元增至2022年的84.93亿元。公司在二级市场也倍受追捧。2020年万泰生物上市后，以近30个涨停板刷新了市场认知，股价最高时，公司市值超过1500亿元。但随着市场竞争的加剧，价格战逐渐升级。2022年，沃森生物的二价HPV疫苗上市，成为第二款获批上市的国产HPV疫苗。作为后来者的沃森生物，同样采用价格战的策略来抢夺市场份额。2022年5月，在江苏省的HPV疫苗竞标中，沃森生物以246元/支的价格获得了高达22400支/瓶的中标量。而万泰生物并未降价，疫苗中标价仍为329元/支，因此只获得了9600支/瓶的中标量。感受到竞争压力的万泰生物，也开始了降价之旅。去年7月，万泰生物以116元/支的价格中标广东省HPV疫苗采购项目，相比2022年已折价过半。量价齐跌，使得万泰生物2023年HPV疫苗收入下降约42亿元。这也导致公司利润大幅下降。面对卖不动的疫苗，万泰生物决定再次反击。此次中标江苏省近50万支疫苗，单价仅86元。相比去年7月再次打了75折。相比最初的329元，更是打了“骨折”。那么，2价HPV疫苗再次大降价后，销量会大幅上涨吗？或者说，销量增长能否弥补降价的影响？情况可能没有那么乐观。因为HPV疫苗领域正在上演一场消费升级。/ 02 /2价跌倒，9价吃饱事实上，对万泰生物的2价HPV疫苗影响最大的并非沃森生物，而是默沙东9价HPV疫苗Gardail9的主动出击。2023年以来，高价HPV疫苗开始加速发力。这一方面是因为，过去防护效果更好的9价HPV疫苗适用人群为16-26岁的女性，而2价和4价HPV疫苗适用人群更为宽泛是9-45岁女性。这导致，部分超龄女性只能选择接种2价和4价HPV疫苗。但如今，青睐高价苗的小姐姐们，已不需要为年龄担心。2022年9月，默沙东的9价HPV疫苗获得国家药品监督管理局批准，适用人群扩大至9-45岁女性。这意味着，此前一部分因年龄限制而只能选择接种2价HPV疫苗的女性，如今或许会转而选择9价HPV疫苗。2价HPV疫苗的目标人群，也由此受到压缩。另一方面则是因为，默沙东4、9价HPV疫苗供应不足的情况，有所缓解。此前，9价HPV疫苗一直处于供不应求状态，甚至需要加价、抢号才能接种，不少人因为预约不到9价疫苗，转而选择2价疫苗。对此，默沙东也一直在不断扩张9价HPV疫苗的产能。此前，默沙东中国CEO田安娜表示，默沙东投入超过10亿美元提高已有的HPV疫苗生产设施产能，随着产能的继续扩大，到2023年供应量预计将再翻一番。事实上，默沙东的9价HPV疫苗产能已经出现明显提升。这使得进口的9价HPV疫苗比以往更容易约上，以至于不少区县的社区卫生服务中心，都发出了9价HPV疫苗免预约接种的通知。2023年，默沙东的Gardail9全球销售额为18.71亿美元，同比增长27%。默沙东在财报中表示，这一业绩主要得益于中国地区的强劲需求。这也在其合作伙伴智飞生物的业绩中得到了体现。去年三季度，智飞生物营收148亿元，同比增长41%；扣非净利润21.69亿元，同比增长15.32%。2024年1月，Gardasil 9的9-14岁女孩二剂次接种程序已获药监局批准。这意味着继2022年Gardasil 9在国内扩龄9-45岁三剂次接种程序后，将新增9-14岁二剂次接种程序，或许其销量还将保持。当然，万泰生物还有机会。毕竟，其在国产9价HPV疫苗研发领域，进度领先。赶在国产9价HPV疫苗密集获批之前上市，其还可以从默沙东手里抢地盘。文／武月【智药研习社近期课程预告】来源：氨基观察声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com▼更多制药资讯，请关注CPHI制药在线▼点击阅读原文，进入智药研习社~

疫苗带量采购核酸药物上市批准信使RNA

2024-03-22

·FiercePharma

Lilly CEO reaffirms commitment to Chinese market amid US threat against local biotechs

Eli Lilly CEO David Ricks “expressed willingness to increase investment in China and reinforce R&D cooperation,” according to China's Ministry of Commerce. At a time of heightened geopolitical tensions between the U.S. and China, Eli Lilly’s CEO said the Indianapolis-based company remains committed to the Chinese market. David Ricks outlined his commitment during a Thursday meeting with China’s Commerce Minister Wang Wentao, according to a press release from the agency. Ricks “expressed willingness to increase investment in China and reinforce R&D cooperation” to better serve the Chinese market, the agency said. Wang, highlighting China’s pharma market as a broad space with room for Lilly and other multinational companies, said he hopes Lilly will continue to invest in China and introduce more drugs, according to the agency’s summary of the meeting. Besides Ricks, Wang also met with CEOs of HP, Visa, Mercedes-Benz Group, semiconductor manufacturer Broadcom, and Estée Lauder this week. Ricks’ visit to China comes as regulators in the country review several Lilly drug applications. These include weight loss drug Zepbound, Alzheimer’s disease therapy donanemab and BTK blood cancer med Jaypirca. At the beginning of the year, Lilly installed a new president of its China business, Huzur Devletsah, who previously headed the firm’s Italian operations. Further, the meeting comes as a draft bill targeting certain Chinese biopharma companies advances in the U.S. Congress. One of the Chinese firms targeted is Lilly’s contractor and partner, WuXi AppTec. The bill, dubbed BIOSECURE Act, aims to block WuXi and other Chinese “biotechnology companies of concern” from getting contracts from federal agencies. If passed in its current form, the bill would also prohibit the targeted firms from working with partners that do business with the federal government, including those who sell drugs to Medicare and Medicaid. Lilly and WuXi teamed up in 2016 to develop a small-molecule drug for lowering blood lipids. WuXi also helps produce the active ingredient used in Zepbound and its sister diabetes drug Mounjaro, according to Bloomberg. Lilly officially started operations in China in 1993. In 2022, its China business was hit hard after Chinese authorities put insulins on a national price-cut program known as volume-based procurement. After the initial effect of the hefty discount passed, Lilly saw its China sales bounce back to grow 6% in 2023 to $1.54 billion. Nevertheless, the growth rate was far slower than the entire firm’s 20%. Meanwhile, the U.S. company hasn’t had the most successful collaborations with Chinese biotechs. Lilly originally partnered with Innovent Biologics on the latter’s PD-1 inhibitor Tyvyt. But it returned U.S. rights to Innovent in 2022 after a high-profile FDA rejection, and it had previously significantly reduced its role in their partnership in China. Lilly China also holds local rights to Hutchmed’s VEGF inhibitor Elunate (fruquintinib), but it later transferred on-the-ground promotion and detailing responsibilities back to Hutchmed. Takeda in 2023 bought ex-China rights to fruquintinib, which was approved by the U.S. FDA in November as a third-line colorectal cancer treatment under the brand name Fruzaqla. Lilly-backed Lilly Asia Ventures has also funded several Chinese biotechs, including Abbisko, Carsgen, Chipscreen Biosciences and others. As tensions between China and the U.S. have intensified in recent months, U.S. pharma companies—compared with their European peers—have largely shied away from making major investments or public endorsements of China. It remains to be seen whether Ricks’ meeting and statement will spur similar visits. Merck & Co., which also works with WuXi, last year surpassed AstraZeneca to become the largest multinational pharma company in China by sales, mainly thanks to the HPV vaccine Gardasil. Merck’s $6.8 billion sales from China in 2023 marked a 31% increase year over year. The New Jersey pharma has also in-licensed several ADCs from China’s Kelun Biotech. At least one other U.S. pharma giant is eying drug innovation out of China. Pfizer CEO Albert Bourla recently talked about tapping “Chinese science” as a source of new medicines. And the New York pharma’s newly minted oncology chief recently told Fierce Pharma that the company is looking for new deals on antibody-drug conjugates (ADCs), including those from China. Last year, Pfizer also signed a memorandum of understanding with the Health China Research Center to support public health research and improve the health of rural populations, although no specific investments have been announced so far. As for European drugmakers, GSK recently inked a high-profile deal with Chongqing Zhifei Biological Products to grow Shingrix in China. As Ricks met with Wang, GSK’s CEO Emma Walmsley also committed to China during her Thursday meeting with Shanghai Mayor Chen Jining, according to a release by the municipal government. And Novo Nordisk just made a large manufacturing investment pledge.

上市批准疫苗

100 项与四价人乳头瘤病毒疫苗（酿酒酵母）相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	四价人乳头瘤病毒疫苗（酿酒酵母）	J07BM01	-

研发状态

适应症	最高研发状态	国家/地区	公司
宫颈癌	批准上市	中国更多	Merck Sharp & Dohme Corp. 更多
肛门癌前病变	批准上市	日本更多	Merck Sharp & Dohme Corp. 更多
人瘤病毒相关性宫颈癌	批准上市	冰岛更多	Merck Sharp & Dohme BV 更多
乳头状瘤病毒感染	批准上市	中国更多	Merck Sharp & Dohme Corp. 更多
尖锐湿疣	批准上市	中国更多	Merck Sharp & Dohme Corp. 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EULAR2020	N/A	风湿性疾病	102	Influenza vaccine	(築鏇鹽築襯艱鬱製簾築) = 廠構醖艱夢鬱獵願齋鑰鬱夢餘餘鬱齋網觸襯鹽 (醖鏇窪鹹餘願構積憲獵 )	-	2020-06-03
				Pneumococcal vaccine	(蓋鏇觸襯醖艱齋鬱夢鑰) = 夢夢鹽獵餘餘繭鑰襯衊積糧憲願夢窪築繭艱齋 (顧壓獵壓壓壓鹹製構糧 )
HIPvac factorial RCT (Pubmed \| Health Technol Assess)	N/A	尖锐湿疣	503	Imiquimod cream	憲艱鹽鑰糧積艱醖糧鑰(衊壓構築簾艱蓋淵蓋鏇): adjusted odds ratio = 0.81 (95% CI, 0.54 ~ 1.23) 更多	-	2020-09-01
				Podophyllotoxin cream
NCT01928225 (CTgov)	临床2期	HIV感染 \| 鳞状上皮内病变	180	Human Papillomavirus vaccine (Human Papillomavirus Vaccine)	餘積鑰願遞顧製繭簾鹽(窪鏇鹹顧廠選餘齋鑰製) = 蓋觸鹹壓憲廠壓繭夢廠廠遞構窪鏇窪鬱鹽窪鹽 (鏇廠繭夢鹹鏇觸糧範憲, 鑰淵觸襯鏇餘艱廠顧醖 ~ 淵鏇齋獵鏇鬱願襯鏇窪) 更多	-	2020-06-24
				Human Papillomavirus vaccine (Saline Placebo)	餘積鑰願遞顧製繭簾鹽(窪鏇鹹顧廠選餘齋鑰製) = 蓋築襯網範鹽憲蓋鬱鬱廠遞構窪鏇窪鬱鹽窪鹽 (鏇廠繭夢鹹鏇觸糧範憲, 膚簾選齋淵選願積憲製 ~ 網糧範繭衊憲選壓淵獵) 更多
ISRCTN33674451 (Pubmed \| Vaccine)	临床3期	HIV血清阳性	372	quadrivalent human papillomavirus vaccine (HIV-positive women)	(齋願襯選觸鹽衊鬱廠糧) = 願餘鏇積顧醖醖窪鑰鑰願夢夢製繭夢觸簾繭顧 (簾顧網鬱鬱簾顧構衊鹽 )	-	2016-09-14
NCT02576054 (V501-200, Pubmed \| Jpn J Infect Dis) 人工标引	临床3期	乳头状瘤病毒感染	99	Quadrivalent HPV Vaccine	(選餘醖築醖壓醖夢顧簾) = 獵網膚獵壓製壓壓淵衊鏇餘窪夢積獵夢餘襯糧 (壓廠鑰鹹窪遞艱獵顧廠, 94.4 ~ 100.0) 更多	积极	2019-09-19
Pubmed \| Clin Infect Dis	临床2期	HIV感染	99	Human Papillomavirus 6, 11, 16, 18 Vaccine (HIV-infected women taking ART)	(鏇襯觸築選膚醖鬱鬱鹽) = One severe adverse event (fatigue) was noted. 選觸簾餘廠淵餘膚繭糧 (艱簾鬱襯鏇衊餘鹹繭憲 )	-	2013-09-01
NCT00423046 (Pubmed \| Hum Vaccin Immunother)	临床3期	-	-	HPV-16/18 AS04-adjuvanted vaccine	(製構繭衊襯顧繭襯獵鏇) = 糧衊壓顧夢鹽構願積願積憲膚憲鏇構製鑰鹹選 (築願餘鬱繭網製獵夢蓋 ) 更多	-	2014-12-02
				HPV-6/11/16/18 vaccine	(範製糧壓廠醖壓鏇顧艱) = 觸鑰蓋艱壓糧餘選夢顧淵構壓齋衊繭獵衊鏇醖 (鹽網膚簾築衊餘膚艱繭 ) 更多
NCT02993757 (CTgov)	临床3期	乳头状瘤病毒感染 \| 严重登革热	528	CYD Dengue Vaccine+Human Papillomavirus Quadrivalent [Types 6, 11, 16, (CYD Dengue Vaccine + Gardasil (Concomitant Administration))	鑰壓夢壓鹹顧遞鹹繭範(廠鹽衊淵網鏇鹹醖糧鑰): GMT ratio = 0.982 (95% CI, 0.664 ~ 1.45); GMT ratio = 0.804 (95% CI, 0.626 ~ 1.03); GMT ratio = 0.815 (95% CI, 0.608 ~ 1.09); GMT ratio = 0.795 (95% CI, 0.603 ~ 1.05) 更多	-	2020-06-11
				CYD Dengue Vaccine+Human Papillomavirus Quadrivalent [Types 6, 11, 16, (CYD Dengue Vaccine + Gardasil (Sequential Administration))
NCT02199691 (CTgov)	临床2期	流行性脑脊髓膜炎	1,715	Meningococcal Polysaccharide (Serogroups A, C, Y,+W135) Tetanus Toxoid Conjugate Vaccine (Group 1: MenACYW Conjugate Vaccine)	構衊餘遞願蓋糧鹽淵膚(窪鹽鑰獵遞襯選鬱襯壓): Percentage Difference = 9.2 (95% CI, 3.4 ~ 15); Percentage Difference = 24.6 (95% CI, 20.3 ~ 29); Percentage Difference = 16.2 (95% CI, 12.3 ~ 20.2); Percentage Difference = 19.6 (95% CI, 14.2 ~ 24.8)	-	2020-06-09
				Meningococcal (Groups A, C, Y+W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (Group 2: MENVEO® Vaccine)
NCT03493542 (CTgov)	临床3期	人瘤病毒相关性宫颈癌 \| 人瘤病毒相关性宫颈原位腺癌 \| 人乳头瘤病毒相关的宫颈上皮内瘤样病变	766	V501 (Chinese Girls Aged 9 to 19 Years)	蓋壓窪廠築糧醖願衊衊(網觸範網憲膚鹽膚淵築): GMT Ratio = 1.42 (95.0% CI, 1.28 ~ 1.58); GMT Ratio = 1.39 (95.0% CI, 1.25 ~ 1.55); GMT Ratio = 1.53 (95.0% CI, 1.37 ~ 1.7); GMT Ratio = 1.66 (95.0% CI, 1.45 ~ 1.9) 更多	-	2020-05-04
				V501 (Chinese Young Women Aged 20 to 26 Years)